| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 7,760 | 1,382,330 | 1,140 | 1,320 | 650 |
| Sales Growth | -99.44% | +121,157.01% | -13.64% | +103.08% | -86.82% |
| Net Income | -63,300 | 1,151,960 | -47,320 | -41,630 | -39,270 |
| Net Income Growth | -105.50% | +2,534.40% | -13.67% | -6.01% | +7.03% |
Zealand Pharma A/S Ord
(ZLDPF)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.
Fiscal Year End Date: 12/31